Yahya Alnujaym, Executive Director for Investment Development at the Saudi Food and Drug Authority (SFDA), participated in the USA–SAUDI Biotech Alliance Summit, a landmark event strengthening scientific and regulatory collaboration between the United States and Saudi Arabia.
With nearly 15 years of leadership experience at SFDA, Alnujaym has contributed to major national and international initiatives, including serving as Director of Standards, ICH Coordinator for Saudi Arabia, and WHO Project Manager. His work has supported the Kingdom’s regulatory transformation and its alignment with global authorities.
At the USA-Saudi Biotech Alliance summit, he emphasized SFDA’s commitment to:
- accelerating the approval of innovative therapies,
- enabling investors through clear regulatory guidance,
- harmonizing with international standards such as ICH,
- leveraging a highly trained team of assessors educated at leading Western institutions.
His remarks reflect Saudi Arabia’s growing role as a competitive, innovation‑ready market for global biotech companies.
OncoDaily LA was present at the summit, documenting key discussions and capturing insights from leaders shaping the future of USA–SAUDI biotech collaboration.